Onyx One Global Study

Studying
1-month DAPT
in high bleeding risk patients with Resolute Onyx DES

Resolute Onyx™ DES (n = 1000) VS. BioFreedom™* DES (n = 1000)

THE FIRST PROSPECTIVE, RANDOMISED
1-MONTH DAPT CLINICAL TRIAL
IN HIGH BLEEDING RISK PATIENTS,
DES VS. DES

KEEP ME INFORMED

DAPT DURATION: DAPT mandated for 1 month, followed by long-term SAPT

PRIMARY ENDPOINT: Composite of cardiac death, myocardial infarction (MI), and stent thrombosis at 1 year

LEAD INVESIGATOR: Stephan Windecker

CO-INVESTIGATORS: Azeem Latib and
Elvin Kedhi

Infographic – High Bleeding Risk Patients — 90 Centres — Clinical Trial Locations
Onyx ONE Physician Discussion

WANT TO
LEARN MORE
ABOUT RESOLUTE ONYX DES?

Discover Resolute
Onyx™ DES

     

  • Caution: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use provided inside the product carton (when available) or at Medtronic.com/emanuals for more detailed information on Indications, Contraindications, Warnings, Precautions, and Adverse Events.
  • Information contained herein for distribution outside the U.S., Canada, Japan, and Australia only. Check the regulatory status of Resolute Onyx™ DES before distribution in areas where CE marking is not the regulation in force.
  • Physician should  consult the most recent ESC guidelines for DAPT to facilitate decision making in their daily practice: Valgimigli et al. 2017 Focused update on Dual Antiplatelet Therapy (DAPT) ESC Clinical Practice Guidelines. European Heart Journal, Volume 39, Issue 3, 14 January 2018, Pages 187–188.

     

ClinicalTrials.gov Identifier: NCT03344653

©2018 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. Not for distribution in the US, Australia, Japan, or France.